Purpose: Preoperative (preop) chemoradiation therapy (CRT) improves local control and reduces toxicity more than postoperative (postop) CRT for the treatment of stages II/III rectal cancer, but studies suggest that many patients still receive postop CRT. We examined patient beliefs and clinical and provider characteristics associated with receipt of recommended therapy.
BACKGROUND
Colorectal cancer (CRC) is the third leading cause of cancer deaths in the United States and was associated with 49,380 deaths in 2011. Of 141,210 incident cases of CRC in 2011, 28% (39, 870) were rectal. 1 Compared with colon cancer, rectal cancer is associated with increased risk of local recurrence and worse overall prognosis. [2] [3] [4] [5] Rectal cancer therapies are also associated with higher morbidity, including problems with bowel function, urinary and fecal continence, and sexual functioning.
The standard of care for stages II and III rectal cancer previously involved surgical resection and postoperative (postop) chemoradiation therapy (CRT). However, more recent studies have shown several advantages to preoperative (preop) CRT including improved local control and reduction in toxicity. [6] [7] [8] Some evidence suggests that preop CRT is also associated with more sphincter-preserving surgeries than postop CRT. 7 Consequently, national guidelines recommend preop CRT for all patients with stages II/III rectal cancer. 9 Although preop CRT is considered the standard of care, many patients still receive postop CRT. Previous studies of stages II/III rectal cancer patients using the Surveillance, Epidemiology, and End Results (SEER) or other registry data found that rates of preop radiation therapy (RT) were increasing as rates of postop RT were decreasing, but substantial treatment variability remained. Among patients diagnosed with rectal cancer between 2003 and 2005 who received both surgery and RT, 60% received preop RT and 40% received postop RT. [10] [11] [12] Studies based on SEER data found that patients receiving preop RT were younger and more likely to be male compared with those receiving postop RT and demonstrated geographic variation. 10, 11 More recent SEER Stat data from 2007 and 2008 indicate that 28% of stages II/III rectal cancer patients who received CRT for rectal cancer still received CRT postoperatively. 13 SEER has limited data on potential explanatory variables for this variation. Using data from the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium, the primary objectives of this study were to characterize in more detail the differences between patients who received preop CRT and those who received postop CRT and the attributes of physicians who practice in any of the participating CanCORS facilities. Although the CanCORS cohort spanned a transitional time period from late 2003 through 2005 during which the proportion of stages II/III rectal cancer patients receiving preop CRT was approximately 60%, relatively little has changed in recent years with just over 70% receiving preop CRT in 2008. Factors associated with receipt of CRT during the CanCORS study period are therefore still very relevant today. In addition, there was at least some awareness of changing guidelines by the beginning of the CanCORS study period, as the National Comprehensive Cancer Network (NCCN) guidelines incorporated preop CRT into their recommended course of treatment in 2003 14 and multiple trials had begun reporting results at national conferences and in journals in 2003. [15] [16] [17] [18] We examined patient beliefs and clinical and provider characteristics associated with receipt of recommended therapy.
MATERIALS AND METHODS
CanCORS is a population-based and health system-based cohort study including approximately 4713 adults with newly diagnosed CRC recruited between 2003 and 2005 from geographically diverse populations and health care systems. It contains detailed information on the acute treatment phase, including surgery, chemotherapy, and RT regimens, and information on the clinical and patient-reported outcomes experienced by the patient. [19] [20] [21] CanCORS participants with stage II or III rectal adenocarcinoma who had primary site resection, RT and chemotherapy initiated within 180 days of surgery, no recurrence within 180 days of diagnosis, and no history of prior cancer were studied. Medical record information was used to assign the American Joint Committee on Cancer collaborative stage. 22 Surgery, RT, and chemotherapy information was extracted from medical records, which covered 30 days before and at least 15 months after diagnosis. Medical record information was reviewed to determine dates of service, radiation dose ( Sequence of visits to the medical oncologist and/or radiation oncologist and the surgeon was also captured. Medical record abstractors were instructed to record all dates associated with patient-provider contacts. For analytic purposes, new consultations, clinical office follow-up notes, emergency department/urgent care clinic visits, radiation treatment visits (with provider contact), chemotherapy, transfusion, or other intravenous medication administration (with physician contact), and patient-to-provider phone calls were considered to be visits. If no visit to a medical oncologist, a radiation oncologist, or a surgeon was recorded before the initiation of their respective therapies/procedures, the first date of treatment was used as the first visit date for that corresponding provider type.
Sociodemographic information (age, sex, education, income, race, and income), health insurance status, patient beliefs, and treatment preferences were obtained from selfreported baseline patient surveys. 20 
Data Analysis
Univariate statistics, w 2 test, Fisher exact test, and Wilcoxon rank sum test were used to compare the preop and postop CRT groups on key variables. Logistic regression was used to model the association between predictors and receipt of preop CRT and obtain both covariate-adjusted predicted proportions and predicted marginal counts of subjects receiving preop CRT. 24 The set of candidate predictive variables included age, sex, race, income, health insurance (none vs. covered by at least 1 insurer/payer), education (no 4-year college vs. at least some 4-year college), marital status (lives alone vs. married or lives with partner), stage of cancer (II vs. III), CanCORS research site affiliation, sequence of physician visits (surgeon first vs. medical and/or radiation oncologist first), documentation of staging procedures, comorbidities (Adult Comorbidity Evaluation-27 categories and individual conditions), tumor size and location, and patient treatment beliefs and preferences. Age and cancer stage were considered key predictors and were not candidates for removal in a backward variable selection procedure used to eliminate noninformative or redundant predictors. Sensitivity analyses limited to patients with documented provider visits before treatment were performed.
A descriptive analysis of a random sample of surgeons, radiation oncologists, and medical oncologists who cared for CanCORS patients in the previous 12 months including those with CRC was also performed. Methods and instruments used in relation to the CanCORS physician survey have been previously described. 25 
RESULTS
Of the 311 CanCORS patients with stages II/III rectal adenocarcinoma and primary site resection, 201 met all inclusion criteria (Fig. 1 ). The characteristics of preop and postop CRT groups are described in Table 1 . Higher proportions of those receiving preop CRT had stage II disease and documentation of a pretreatment MRI of the pelvis or rectal EUS and CT of the chest. Those receiving postop CRT had a higher proportion of tumors located at the rectosigmoid junction, significantly larger tumors, and angina/coronary artery disease. There were no differences in demographics, such as age, sex, ethnicity, marital status, education, income, or insurance status, between groups.
The 2 groups differed significantly in the sequence of their provider visits. Forty-four percent of those who received preop CRT visited a medical or radiation oncologist before visiting a surgeon, whereas only 4% of those who received postop CRT visited a medical or radiation oncologist before visiting a surgeon, and 71% of the preop group visited a surgeon and a medical or radiation oncologist before receiving any treatment compared with 13% of the postop group.
There were no significant differences between those who received preop and postop CRT in their preferred decisionmaking roles and beliefs related to RT, surgery, and chemotherapy, with 2 exceptions. A higher proportion of people who received postop CRT reported that RT would very likely or somewhat likely cure their cancer compared to those who received pre-op CRT (86% vs 61%, respectively; P < 0.01). Conversely, a higher proportion of people who received preop CRT reported that the RT would very likely or somewhat likely help with the symptoms they were having from their cancer compared to those who received post-op CRT (88% vs 73%, respectively; P = 0.04). Almost all respondents reported receiving high-quality care from their providers, with no differences by preop/postop CRT status. Approximately half of respondents reported that they made the decision to have CRT and surgery together with their doctors and approximately one-third said they made the decision after considering the doctors' opinions. The remaining 15% of respondents were split between reporting that their doctors made the decision after considering their opinions or that their doctors made the decision with little or no input from them, with no differences by pre-op/post-op CRT status. Almost all respondents reported beliefs that chemo and RT would have side effects or complications, whereas only about half of respondents reported beliefs that surgery would have side effects or complications. Sixty percent of respondents reported a preference for treatment that extends life as much as possible, as opposed to a preference for treatment that focuses on relieving pain/discomfort as much as possible, even it means not living as long. Likewise, 70% of patients reported a preference for treatment that extends life as much as possible, even if it means using up financial resources, as opposed to a preference for treatment that costs less, even if it means not living as long. Again, there were no differences by pre-op/post-op CRT status.
The adjusted probabilities of receiving preop CRT based on the characteristics of 201 patients in the final logistic model are displayed in Table 2 . Subjects visiting a medical or radiation oncologist before a surgeon had a 96% (95% confidence interval [CI], 92%-100%) adjusted probability of receiving preop CRT, whereas those visiting a surgeon first had a 48% (95% CI, 41%-55%) adjusted probability of receiving CRT. In addition, those who visited a surgeon and a medical or radiation oncologist before any treatment had a 92% (95% CI, 87%-97%) adjusted probability of receiving preop CRT, whereas those visiting only a surgeon or a medical or radiation oncologist had a 32% (95% CI, 25%-39%) adjusted probability. No other patient characteristics remained significant in this model. Sensitivity analyses limited to those with documented visits before treatment yielded very similar results.
As there was virtually no variation in CRT-surgery sequence among those who visited a medical or radiation oncologist before a surgeon, but there was substantial variation among those who visited a surgeon first, we created a separate logistic model for those 140 subjects ( Table 2 ). Among patients who saw a surgeon first, those who had documentation of a pelvic MRI or EUS had a 74% (95% CI, 62%-85%) adjusted probability of receiving preop CRT, whereas the others had a 40% (95% CI, 30%-50%) adjusted probability. Also, those who had a documentation of a chest CT were more likely to have preop CRT.
We reported survey results from surgeons, radiation oncologists, and medical oncologists who had cared for at least 1 CanCORS CRC patient in the previous 12 months in Table 3 . The most notable differences among these provider types were related to the volume of CRC patients treated in the last month and the percentage reporting weekly attendance at multidisciplinary meetings (eg, tumor boards). Medical oncologists, radiation oncologists, and surgeons reported seeing a median of 10, 3, and 3 CRC patients in the last month, respectively, and 67%, 82% and 36% reported attending weekly multidisciplinary meetings, respectively.
A description of treatment characteristics and their association with the sequence of CRT and surgery is provided in Table 4 . Those who received preop CRT were more likely to have been given the standard total RT dose of 4500 to 5040 cGy and to have had an APR approach, whereas the postop CRT patients were more likely to have been given a dose >5040 cGy and have had an LAR approach. There were no significant differences in chemotherapy regimens or number of days between initiation of CRT and surgery.
DISCUSSION
Consistent with previous evaluations of SEER data, we found that 34% of patients with stages II/III rectal cancer received postop CRT. Unlike those studies, we did not find significant differences in use of preop versus postop CRT related to patient sex or age. 10, 11 Rather, our findings suggest that provider characteristics play a larger role in determining sequencing of rectal cancer therapies than patient characteristics. After accounting for multiple factors, nearly all subjects visiting a medical and/or radiation oncologist before visiting a surgeon received preop CRT, whereas only 48% of those who visited a surgeon first received preop CRT. Similar to our study, Luo et al 26 reported that referral to a medical oncologist was the most important factor associated with receipt of chemotherapy among older patients with stage III colon cancer. However, no other studies have reported on the significance of the visit sequence of surgeons and oncologists. It is possible that the visit sequence variables available in CanCORS, which are not available in SEER, are far stronger predictor variables than age and sex and explain the difference in findings among the studies.
Among those who visited a surgeon first, we found that patients who had a pelvic MRI or EUS and a chest CT were more likely to receive preop CRT. It is possible that access to EUS was an issue for some patients and that pelvic MRI had not been adopted by some providers as an acceptable alternative; thus, the decision was made to perform surgery first. In addition, receipt of these recommended staging procedures may be a proxy measure capturing quality care provided by physicians experienced in treating patients with rectal cancer. Although characteristics of specific providers treating patients in our study were not available, we evaluated the overall CanCORS CRC provider population. Surgeon respondents were less likely than medical or radiation oncologists to report attendance at multidisciplinary meetings to discuss cancer care (eg, tumor boards) at least weekly. This may indicate that some surgeons do not treat a high enough volume of rectal cancer patients to be familiar with changing guidelines for care. We found that the median number of CRC patients evaluated in the previous month by the surgeon respondents was 3, and the median number of colon or rectal resections per month was 2; fewer than half of those are likely to be rectal resections. Another analysis of CanCORS data found that those surgeons identifying themselves as colorectal surgeons or surgical oncologists (16%) were more likely to report high volumes of CRC resections and high-volume surgeons were more likely to report collaborative decision-making with other physicians on adjuvant therapies. 27 Several studies have previously shown that surgeon specialty influences patient management in CRC care. One study showed that patients treated by colorectal surgeons were far more likely to receive preop CRT than those treated by general surgeons (91% vs. 17%). 28 A survey of surgeons in Florida also found that general surgeons were significantly less likely than colorectal surgeons or surgical oncologists to refer their patients for preop CRT and less likely to report adherence to the NCCN recommended staging guidelines. 29 A survey of Canadian surgeons yielded similar results regarding recommended staging procedures. 30 Other studies have linked specialty training and/or surgeon volume of CRC patients treated annually with receipt of recommended treatment and better outcomes. [31] [32] [33] Interestingly, in contrast to other gastrointestinal malignancies, there has been no evidence of shift toward high-volume centers for rectal cancer cases. 34, 35 Our findings suggest that patients' beliefs about the effects of radiation treatment are influenced by the order in which treatments are recommended to them. In unadjusted analyses, a higher proportion of people who received postop CRT reported belief that RT would very likely or somewhat likely cure their cancer, whereas a higher proportion of patients who received postop CRT believed RT would not be likely to help with their symptoms. That seeing a surgeon first removed this association in multivariate models suggests that it was the sequence of visits that mediated the difference between preop and postop patient beliefs. The phrasing of the survey items to elicit beliefs after discussing treatment with their physicians (ie, "after talking with your doctors about radiation therapy, how likely did you think it was thaty.") further supports a direct influence of physician visit sequence and not merely selection of patients who innately believe in the curability of cancer to seek out surgeons first. It is noteworthy that nearly all subjects, regardless of treatment sequence, rated their quality of care good to excellent for surgery, RT, and chemotherapy.
With respect to subsequent treatment regimen characteristics, a higher proportion of those who underwent preop CRT received standard doses of radiation (4500 to 5040 cGy in 25 to 28 fractions regardless of the sequence of RT and surgery), 9 whereas a higher proportion of those who underwent postop CRT received a higher dose of radiation ( > 5040 cGy). We hypothesized that among patients who underwent surgery as first-line treatment, those who had positive surgical margins may have been given a higher radiation dose postoperatively. However, there were only 2 postop CRT subjects with documented positive margins, and only one of those had a higher than normal dose of radiation. As the postop surgical bed is associated with more damage to blood vessels and diminished blood flow and oxygen supply, some radiation oncologists may use a higher dose to achieve better local control. 36 Patients who received preop CRT were more likely to have open APR approach, whereas those who received postop CRT were more likely to have an LAR approach, which is not consistent with results of other studies of preop and postop CRT. 7, 37, 38 It is possible that surgeons are more likely to refer patients with low rectal tumors for preop CRT in attempts to reduce the tumor size sufficiently enough to allow for the sphincter-sparing LAR approach. Preop CRT may not be able to always achieve this objective in many instances, and the APR approach may still be necessary.
This study has some potential limitations. Staging was based upon the highest level of pathologic and clinical information available in the medical record. Thus, it is possible that some of the patients receiving postop CRT could have been clinically staged as stage I and consequently received first-line surgery and were then found to have stages II/III rectal cancer during surgery and received postop CRT. However, those who received postop CRT were less likely to have documentation of a chest CT or pelvic MRI/EUS in their medical record as part of clinical staging. The NCCN guidelines indicate that all rectal patients should have pelvic MRI or EUS and a CT of the chest, abdomen, and pelvis to rule out metastases to the liver and lung. 9, 39 Thus, some patients may have failed to receive the recommended treatment for stages II/III rectal cancer due to inaccurate staging. Some patients with rectal cancer present emergently with bleeding or obstructing tumors. As a result, it is reasonable to expect that a small portion of patients may have initial surgery for symptom control. Still, even among cases of bleeding or obstruction, symptoms can often be controlled with a diverting ostomy and CRT; therefore, this does not justify the large differences in rates of preop CRT.
In conclusion, a substantial proportion of patients with stages II/III rectal cancer received postop CRT despite compelling evidence supporting preop CRT. Receipt of preop CRT was associated with visits to medical or radiation oncologists before surgeons and visits to multiple provider types before initiation of treatment. The increased participation of oncologists (compared with surgeons) in multidisciplinary team conferences, which have been shown to improve processes and outcomes of care for CRC patients, 40 is a potential driver of the observed association and an ideal target for national quality improvement initiatives. It is also possible that the decision to perform postop CRT may have been related to patient preference, lack of access to recommended staging procedures, or other logistic factors that created justifiable circumstances. Consequently, further evaluation of patient treatment preferences, provider characteristics, presence of multidisciplinary treatment planning, access/availability of staging procedures, referral patterns, and health system processes that determine treatment should be undertaken to understand variation from recommended care and design targeted interventions to improve quality of care.
